Active	Status	Sponsor type	Region	Phase	Filter
1 Active 12 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Carcinoma, Large Cell
NCT02784158: An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer	No Longer Available	N/A		US	Brigatinib, AP26113	Ariad Pharmaceuticals	Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies, Carcinoma

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Carcinoma, Large Cell
NCT02784158: An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer	No Longer Available	N/A		US	Brigatinib, AP26113	Ariad Pharmaceuticals	Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies, Carcinoma